Rhodiola rosea: what the adaptogen research actually shows

Rhodiola rosea is a perennial herb native to mountainous regions of Europe and Asia. It's sold as a supplement for stress and fatigue under the "adaptogen" label, a category coined in Soviet-era pharmacology to describe agents claimed to non-specifically improve resistance to stress.

The research base#

Rhodiola has a moderate number of human RCTs, mostly from Scandinavian and Russian research groups, in stress-related fatigue and burnout populations:

• Olsson et al. 2009 (Planta Medica): 4 weeks of standardised rhodiola extract (SHR-5) in 60 adults with stress-related fatigue. Improvements in fatigue, attention, and cortisol response versus placebo.
• Edwards et al. 2012: open-label work in adults with life-stress symptoms, suggestive but not blinded.
• Cropley et al. 2015: 14-day daily dosing effects on mood in mildly anxious adults.
• Bystritsky et al. 2008 — generalised anxiety pilot trial, small.

A 2022 review (Ivanova Stojcheva & Quintela) summarised the clinical literature on rhodiola for stress-related fatigue and described the evidence as encouraging. Most trials are small, short, and use the same standardised extract.

What the trials actually measure#

The endpoint that comes up most consistently is subjective fatigue and burnout scales: Pines Burnout Measure, Multidimensional Fatigue Inventory, similar. Improvements are typically in the 10–25% range over placebo. Cognitive task performance shows smaller, less consistent effects.

These are not large effects. They are also not absent.

Dose and form#

Most published trials use standardised SHR-5 extract at 200–600 mg/day, taken in the morning. Different extracts are not equivalent; rhodiola is rich in active compounds (rosavins, salidrosides) that vary widely between products. The 3% rosavin / 1% salidroside ratio used in most trials is a reasonable default.

What "adaptogen" actually means#

The adaptogen category lacks a regulator-defined meaning in the UK. The MHRA does not licence any rhodiola product as a medicine; products are sold as food supplements. Claims must comply with Nutrition and Health Claims Regulation; sweeping wellness claims about adaptogenic effects are not on the approved-claims list.

Side effects and interactions#

Rhodiola is generally well-tolerated in trials. Reported side effects include dry mouth, dizziness, and occasional excitability or sleep disturbance, particularly when taken later in the day.

Interactions to know about:

• Rhodiola has some serotonergic activity; combining with SSRI antidepressants or MAOIs is not advised without clinical input.
• It may potentiate stimulants.
• People with bipolar disorder should not take rhodiola without psychiatric input; activating effects are a documented concern.

The honest summary#

Rhodiola has the strongest evidence base of any "adaptogen", which is itself a low bar. The trial data support a modest, real effect on subjective fatigue and burnout symptoms in mildly stressed adults. Effects are not transformative, the literature is small, and the trial quality is moderate at best.

For someone with mild stress-related fatigue who has slept, eaten, exercised, and addressed obvious lifestyle factors, a 4-week trial of standardised rhodiola at the published dose is a reasonable experiment with low downside risk and modest expected upside. It is not a treatment for clinical anxiety, depression, or burnout; those require proper clinical care.